- Clinical outcomes of atezolizumab in combination with etoposide/platinum for extensive-stage small cell lung cancer in China: A real-world, multi-center, retrospective, controlled studyZhuo, M.; Chen, H.; Ma, X.; Liu, J.; Yang, Y.; Fang, Y.; Wang, L.; Zhao, J.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 1
- A dedicated lung cancer immunotherapy outpatient clinic: The first experience in China.Xu, Chongrui; Tu, Hai-Yan; Sun, Yueli; Li, Yang-Si; Xu, Bing-Fei; Wang, Bin-Chao; Chen, Hua-Jun; Wang, Zhen; Zhou, Qing; Yang, Jin-Ji; Li, Chanchan; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2020-05-29 To 2020-05-31.
- Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)Xu, C.; Chen, Q.; Zhou, C.; Wu, L.; Li, W.; Zhang, H.; Li, Y.; Xu, F.; Xiong, J.; Wang, Q.; Zhang, H.; Jiang, Y.; Yin, H.; Wu, Q.; Dai, Q.; Hu, J.; Chen, J.; Zhang, J.; Wu, G.; Wu, Y-L.ESMO Immuno-Oncology Congres, ELECTR NETWORK, 2021-12-08 To 2021-12-11.被引 2
会议论文
Adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A single center, real-world study in China.
5阅读
